Severance Hospital is a hospital located in Sinchon-dong, Seodaemun District, South Korea. It is one of the oldest and biggest university hospitals in South Korea. It has 2,437 beds and treats approximately 2,500,000 outpatients and 840,000 inpatients annually.

During the past decade, Severance Hospital, Yonsei University Health System conducted 640 clinical trials. In the 10-year time frame, 640 clinical trials started and 185 clinical trials were completed, i.e. on average, 28.9% percent of trials that started reached the finish line to date. In the past 5 years, 366 clinical trials started and 136 clinical trials were completed. i.e. 37.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Severance Hospital, Yonsei University Health System" #1 sponsor was "Yonsei University" with 145 trials, followed by "Hoffmann-La Roche" with 76 trials sponsored, "Pfizer" with 65 trials sponsored, "Janssen Research & Development, LLC" with 34 trials sponsored and "Eli Lilly and Company" with 34 trials sponsored. Other sponsors include 405 different institutions and companies that sponsored additional 194 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Severance Hospital, Yonsei University Health System" #1 collaborator was "Merck Sharp & Dohme LLC" with 17 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 11 trials as a collaborator, "AstraZeneca" with 9 trials as a collaborator, "Eli Lilly and Company" with 9 trials as a collaborator and "National Cancer Institute (NCI)" with 8 trials as a collaborator. Other collaborators include 179 different institutions and companies that were collaborators in the rest 128 trials.

According to Clinical.Site data, the most researched conditions in "Severance Hospital, Yonsei University Health System" are "Breast Cancer" (24 trials), "Gastric Cancer" (16 trials), "Ulcerative Colitis" (16 trials), "Ovarian Cancer" (13 trials) and "Non-small Cell Lung Cancer" (12 trials). Many other conditions were trialed in "Severance Hospital, Yonsei University Health System" in a lesser frequency.

Most popular intervention types in "Severance Hospital, Yonsei University Health System" are "Drug" (602 trials), "Device" (50 trials), "Other" (49 trials), "Biological" (46 trials) and "Procedure" (38 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (145 trials), "Atezolizumab" (37 trials), "Carboplatin" (28 trials), "Paclitaxel" (28 trials) and "Pembrolizumab" (23 trials). Other intervention names were less common.

The vast majority of trials in "Severance Hospital, Yonsei University Health System" are 664 trials for "All" genders, 61 trials for "Female" genders and 33 trials for "Male" genders.

Currently, there are 407 active trials in "Severance Hospital, Yonsei University Health System". 40 are not yet recruiting, 222 are recruiting, 142 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 263 completed trials in Severance Hospital, Yonsei University Health System, undefined suspended trials, and 46 terminated clinical trials to date.

Out of the total trials that were conducted in Severance Hospital, Yonsei University Health System, 130 "Phase 1" clinical trials were conducted, 228 "Phase 2" clinical trials and 274 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 34 trials, and there were also 89 trials that are defined as “Not Applicable".